Pinion Investment Advisors LLC Boosts Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Pinion Investment Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 100.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 150,000 shares of the biotechnology company's stock after acquiring an additional 75,000 shares during the period. Pinion Investment Advisors LLC owned approximately 0.11% of Arrowhead Pharmaceuticals worth $1,911,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Avoro Capital Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 25.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock valued at $208,889,000 after acquiring an additional 2,222,223 shares during the last quarter. Norges Bank bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $38,622,000. Farallon Capital Management LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $11,821,000. Two Sigma Investments LP increased its position in shares of Arrowhead Pharmaceuticals by 281.3% in the fourth quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company's stock worth $14,934,000 after purchasing an additional 586,062 shares during the period. Finally, Slate Path Capital LP raised its position in shares of Arrowhead Pharmaceuticals by 7.1% in the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock valued at $98,362,000 after buying an additional 347,000 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ARWR has been the topic of several research reports. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Finally, Citigroup cut their price objective on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.71.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock traded up $0.12 during mid-day trading on Wednesday, reaching $15.62. 1,139,339 shares of the company's stock were exchanged, compared to its average volume of 1,886,826. The business's fifty day simple moving average is $14.44 and its 200 day simple moving average is $17.05. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 0.31. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $30.41. The firm has a market capitalization of $2.16 billion, a PE ratio of -11.16, a P/E/G ratio of 18.47 and a beta of 0.96.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to analysts' expectations of $116.27 million. During the same period in the prior year, the business earned ($1.02) earnings per share. On average, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the company's stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the sale, the chief executive officer now owns 3,921,255 shares of the company's stock, valued at approximately $45,055,219.95. This represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.